Rachel Epstein, MD, MScE

Assistant Professor, Medicine

Rachel Epstein

Biography

Rachel L. Epstein, MD, MScE, is a clinician-scientist working to utilize large data sets and decision modelling to inform policy and program design to improve care for individuals with Hepatitis C, HIV, and substance use, with a particular focus on pregnant women and youth.

Dr. Epstein completed combined residency training in internal medicine-pediatrics at Brown University, and worked in primary care through the Providence Community Health Centers and the Hasbro Adolescent Center before fellowship. She completed a combined adult and pediatric infectious diseases fellowship at Boston Medical Center and a T32 post-doctoral research fellowship through the Boston University Clinical HIV/AIDS Research Training Program (BU-CHART). She is an Assistant Professor in the BUSM Department of Medicine, Section of Infectious Diseases, and Department of Pediatrics, Section of Infectious Diseases and sees adult and pediatric patients living with or at risk for Hepatitis C virus, HIV, and other infectious diseases. She also serves as the Med-Peds faculty specific advisor lead for BUSM students.

Dr. Epstein’s current and recent work includes projects analyzing the effects of Medicaid HCV treatment restrictions on care cascade outcome achievement, HIV prevention and medication adherence, and comparing the cost-effectiveness of HCV and OUD screening, evaluation, and treatment interventions in women of reproductive age, children, and the general population. She currently or previously works/worked with data through OCHIN, TriNetX, the BMC Datawarehouse and COVID-19 Repository, Marketscan, and the Massachusetts Public Health Datawarehouse.

Other Positions

  • Assistant Professor, Pediatrics, Boston University Chobanian & Avedisian School of Medicine

Education

  • Thomas Jefferson University, MD
  • Boston University School of Public Health, MSc
  • Wesleyan University, MA
  • Wesleyan University, BA

Publications

  • Published on 3/11/2024

    Curtis MR, Epstein RL, Pei P, Linas BP, Ciaranello AL. Cost-Effectiveness of Strategies for Treatment Timing for Perinatally Acquired Hepatitis C Virus. JAMA Pediatr. 2024 Mar 11. PMID: 38466273.

    Read at: PubMed
  • Published on 2/7/2024

    Epstein RL, Buzzee B, White LF, Feld JJ, Castera L, Sterling RK, Linas BP, Taylor LE. Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus. J Viral Hepat. 2024 Feb 07. PMID: 38326950.

    Read at: PubMed
  • Published on 2/1/2023

    Epstein RL, Pramanick T, Baptiste D, Buzzee B, Reese PP, Linas BP, Sawinski D. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers. J Am Soc Nephrol. 2023 Feb 01; 34(2):205-219. PMID: 36735375.

    Read at: PubMed
  • Published on 12/1/2022

    Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch CT, Justice AC, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, D'Arminio Monforte A, Gill J, Salmon Ceron D, van Sighem A, Linas B, van der Valk M, HernĂ¡n MA. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection. J Int AIDS Soc. 2022 Dec; 25(12):e26048. PMID: 36562643.

    Read at: PubMed
  • Published on 8/24/2022

    Barocas JA, Savinkina A, Lodi S, Epstein RL, Bouton TC, Sperring H, Hsu HE, Jacobson KR, Schechter-Perkins EM, Linas BP, White LF. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. Clin Infect Dis. 2022 Aug 24; 75(1):e1112-e1119. PMID: 34499124.

    Read at: PubMed
  • Published on 6/30/2022

    Sperring H, Hofman M, Hsu HE, Xiao Y, Keohane EA, Lodi S, Marathe J, Epstein RL. Risk Factors for Admission Within a Hospital-Based COVID-19 Home Monitoring Program. Open Forum Infect Dis. 2022 Jul; 9(7):ofac320. PMID: 35899280.

    Read at: PubMed
  • Published on 6/18/2022

    Epstein RL, Wang J, White LF, Kapadia SN, Morgan JR, Bao Y, Linas BP. Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured. Am J Prev Med. 2022 Sep; 63(3):e87-e98. PMID: 35725599.

    Read at: PubMed
  • Published on 5/22/2022

    Nguemeni Tiako MJ, Meinhofer A, Friedman A, South EC, Epstein RL, Meisel ZF, Morgan JR. Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorder. Am J Obstet Gynecol. 2022 Sep; 227(3):544-546.e1. PMID: 35613648.

    Read at: PubMed
  • Published on 5/13/2022

    O'Donnell A, Pham N, Battisti L, Epstein R, Nunes D, Sawinski D, Lodi S. Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection. PLoS One. 2022; 17(5):e0268478. PMID: 35560032.

    Read at: PubMed
  • Published on 7/1/2021

    Epstein RL, Moloney C, Garfinkel J, Saia K, Wachman EM, Lodi S, Pelton SI. Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care. Hepatol Commun. 2021 Sep; 5(9):1543-1554. PMID: 34510828.

    Read at: PubMed

View 10 more publications: View full profile at BUMC

View all profiles